OVERVIEW

Expertise in Obesity Clinical Trial Delivery

Pathway to Success - From Start to Finish

PPD, a part of Thermo Fisher Scientific, shares your passion for developing novel therapies for obesity and offers concrete data-driven and tested solutions for the successful clinical execution of your trial. PPD has significant experience conducting obesity studies, which includes patient centric strategies and a standardized nutritional & lifestyle program managed by an in-house dietician. In addition, PPD's experience in GLP-1RA trials in T2 diabetes can be leveraged to address specific challenges of studies which have used GLP-1RAs in non-diabetic patients too.

16 Obesity Phs II-IV studies in the past 5 years recruiting 8,500+ patients

Obesity-experienced operations staff, including 7 in-house endocrinologists with obesity experience

PPD's **proprietary patient database** with demographic data. **313K+** households globally with ≥1 persons reporting obesity; **309K+** in the US.

Leader in digital solutions – Reduce patient burden, promote patient retention, and drive high patient data compliance

GCL: >3500 sites, 69 countries. Over **2M samples** analysed across **273 studies** (Phs I-IV). In house analysis of metabolic specific biomarkers

GLP-1RA experience; PPD has managed 16 GGLP-1RAs, GLP-1/GIP Receptor (dual) agonists or GLP-1/GIP/GCGR (triple) T2DM

Partner with PPD and benefit from our:

- **Depth of experience** in all stages of metabolic drug development and a dedicated global team with deep experience providing consistent quality delivery across all regions
- **Depth of understanding** of the medical and regulatory requirements for obesity studies
- **Strong site relationships** and high-enrolling, PPD known sites to ensure successful study execution
- **Provision of educational materials** for sites and a PI educational playbook – motivational interviewing to help recruit the RIGHT patient
- **A centralized nutritional & lifestyle program** that provides a standardized approach that is implemented by the sites which lessens the risk of inter-site variability and reduces the need for a site registered dietician
- **Integrated digital solutions** where different apps and wearables (e.g. CGM, activity trackers) are feeding automatically into an eDiary kept by the patient during the clinical study
- **PPD's home health services** to minimize patient burden, allowing for some visits to happen at home
- **Recruitment and retention materials** developed to address the specific challenges of obesity studies targeting not only the patient, but also the patient's surroundings (e.g. info-sheets, counseling). Providing tools and incentives to keep patients motivated, specially in placebo controlled trials, minimizing dropout rate.
- **Continuous Glucose Monitoring (CGM) offering** with parsing and visualization of overall "real time' data onto customized patient dashboards
- **Comprehensive global BioA and central lab services**
- **Patient concierge services** that provide appointment reminders, assist with transportation, medication reminders, and enhance patient experience
- **Scientific surveillance** - sophisticated statistical monitoring to minimize risk associated with lifestyle marker variability, premature discontinuations and site variability
- **PPDs Cardiovascular Kidney Metabolic (CKM) Centre of Excellence** supports clients with seamless cross- collaborative operational, medical and scientific expertise across the spectrum of metabolic diseases and their comorbidities

PPD's Proven Track Record

- Increased Site Engagement
- Quick Site Activations
- High Enrollment Rates
- Quality Data

Scan to Learn More

www.ppd.com